期刊文献+

Management of functional dyspepsia: Unsolved problems and new perspectives 被引量:3

Management of functional dyspepsia: Unsolved problems and new perspectives
下载PDF
导出
摘要 The common characteristic criteria of all functional gastrointestinal(GI)disorders are the persistence and recurrence of variable gastrointestinal symptoms that cannot be explained by any structural or biochemical abnormalities. Functional dyspepsia (FD) represents one of the important GI disorders in Western countries because of its remarkably high prevalence in general population and its impact on quality of life. Due to its dependence on both subjective determinants and diverse country-specific circumstances, the definition and management strategies of FD are still variably stated.Clinical trials with several drug classes (e.g., proton pump inhibitors, H2-blockers, prokinetic drugs) have been performed frequently without validated diseasespecific test instruments for the outcome measurements.Therefore, the interpretation of such trials remains difficult and controversial with respect to comparability and evaluation of drug efficacy, and definite conclusions can be drawn neither for diagnostic management nor for efficacious drug therapy so far. In view of these unsolved problems, guidelines both on the clinical management of FD and on the performance of clinical trials are needed. In recent years, increasing research work has been done in this area. Clinical trials conducted in adequately diagnosed patients that provided validated outcome measurements may result in better insights leading to more effective treatment strategies.Encouraging perspectives have been recently performed by methodologically well-designed treatment studies with herbal drug preparations. Herbal drugs, given their proven efficacy in clinical trials, offer a safe therapeutic alternative in the treatment of FD which is often favored by both patients and physicians. A fixed combination of peppermint oil and caraway oil in patients suffering from FD could be proven effective by well-designed clinical trials. The common characteristic criteria of all functional gastrointestinal (GI) disorders are the persistence and recurrence of variable gastrointestinal symptoms that cannot be explained by any structural or biochemical abnormalities. Functional dyspepsia (FD) represents one of the important GI disorders in Western countries because of its remarkably high prevalence in general population and its impact on quality of life. Due to its dependence on both subjective determinants and diverse country-specific circumstances, the definition and management strategies of FD are still variably stated. Clinical trials with several drug classes (e.g., proton pump inhibitors, H2-blockers, prokinetic drugs) have been performed frequently without validated disease- specific test instruments for the outcome measurements. Therefore, the interpretation of such trials remains difficult and controversial with respect to comparability and evaluation of drug efficacy, and definite conclusions can be drawn neither for diagnostic management nor for efficacious drug therapy so far. In view of these unsolved problems, guidelines both on the clinical management of FD and on the performance of clinical trials are needed. In recent years, increasing research work has been done in this area. Clinical trials conducted in adequately diagnosed patients that provided validated outcome measurements may result in better insights leading to more effective treatment strategies. Encouraging perspectives have been recently performed by methodologically well-designed treatment studies with herbal drug preparations. Herbal drugs, given their proven efficacy in clinical trials, offer a safe therapeutic alternative in the treatment of FD which is often favored by both patients and physicians. A fixed combination of peppermint oil and caraway oil in patients suffering from FD could be proven effective by well-designed clinical trials.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第42期6577-6581,共5页 世界胃肠病学杂志(英文版)
关键词 消化不良 透视检查 临床表现 治疗 Dyspepsia Functional dyspepsia Definition Diagnosis Management Drug efficacy Clinical trials Outcome measurements Herbal drugs
  • 相关文献

参考文献50

  • 1[1]Malfertheiner P.Current concepts in dyspepsia:a world perspective.Eur J Gastroenterol Hepatol 1999; 11 Suppl 1:S25-S29
  • 2[2]Knill-Jones RP.Geographical differences in the prevalence of dyspepsia.Scand J Gastroenterol Supp11991; 182:17-24
  • 3[3]Johannessen T,Petersen H,Kristensen P,Kleveland PM,Dybdahl J,Sandvik AK,Brenna E,Waldum H.The intensity and variability of symptoms in dyspepsia.Scand J Prim Health Care 1993; 11:50-55
  • 4[4]Jones R,Lydeard S.Dyspepsia in the community:a follow-up study.Br J Clin Pract 1992; 46:95-97
  • 5[5]Talley NJ.Helicobacter pylori and dyspepsia.Yale J Biol Med1999; 72:145-151
  • 6[6]Talley NJ,Stanghellini V,Heading RC,Koch KL,Malagelada JR,Tytgat GN.Functional gastroduodenal disorders.Gut 1999;45 Suppl 2:Ⅱ37-Ⅱ42
  • 7[7]Talley NJ,Stanghellini V,Heading RC,Koch KL,Malagelada JR,Tytgat GN.Functional gastroduodenal disorders.Gut 1999;45 Suppl 2:Ⅱ37-Ⅱ42
  • 8[8]Thompson WG,Longstreth GF,Drossman DA,Heaton KW,Irvine EJ,Muller-Lissner SA.Functional bowel disorders and functional abdominal pain.Gut 1999; 45 Suppl 2:Ⅱ43-Ⅱ47
  • 9[9]Spiller R.Rome Ⅱ:the functional gastrointestinal disorders.Diagnosis,pathophysiology and treatment:a multinational consensus.Gut 2000; 46:741B
  • 10[10]Mullins PD,Colin-Jones DG.Guidelines for the management of dyspepsia.Eur J Gastroenterol Hepatol 1999; 11:215-217

同被引文献16

  • 1Rok Son Choung,Nicholas J Talley.Novel mechanisms in functional dyspepsia[J].World Journal of Gastroenterology,2006,12(5):673-677. 被引量:25
  • 2Klaus Mnkemüller,Peter Malfertheiner.Drug treatment of functional dyspepsia[J].World Journal of Gastroenterology,2006,12(17):2694-2700. 被引量:9
  • 3Nadia Pallotta,Patrizio Pezzotti,Enrico Corazziari.Relationship between antral distension and postprandial symptoms in functional dyspepsia[J].World Journal of Gastroenterology,2006,12(43):6982-6991. 被引量:7
  • 4Joan Monés,Ana Adan,José L. Segú,Juan S. López,Maite Artés,Tina Guerrero.Quality of Life in Functional Dyspepsia[J].Digestive Diseases and Sciences.2002(1)
  • 5R. D. Hays,R. Anderson,D. Revicki.Psychometric considerations in evaluating health-related quality of life measures[J].Quality of Life Research.1993(6)
  • 6Piessevaux H,De Winter B,Louis E,Muls V,De Looze D,Pelckmans P,Deltenre M,Urbain D,Tack J.Dyspeptic symptoms in the general population:a factor and cluster analysis of symptom groupings[].Neurogastroenterology and Motility.2009
  • 7Kang XQ,Liu ZW,Xie B,Niu XY,Xiao YY,He C.The incidence of Functional Dyspepsia of parts of citizens in Tianjin[].Chinese Journal of Digestion.2002
  • 8Meineche-Schmidt V,Talley NJ,Pap A,Kordecki H,Schmid V,Ohlsson L,Wahlqvist P,Wiklund I,Bolling-Sternevald E.Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment.A multicentre3-month follow-up study[].Scandinavian Journal of Gastroenterology.1999
  • 9Rentz AM,Battista C,Trudeau E,Jones R,Robinson P,Sloan S,Mathur S,Frank L,Revicki DA.Symptom and health-related quality-of-life measures for use in selected gastrointestinal disease studies:a review and synthesis of the literature[].Pharmacoeconomics.2001
  • 10Hashash JG,Abdul-Baki H,Azar C,ElhajjⅡ,El Zahabi L,Chaar HF,Sharara AI.Clinical trial:a randomized controlled cross-over study of flupenthixol+melitracen in functional dyspepsia[].Alimentary Pharmacology and Therapeutics.2008

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部